Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AKFYV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Raludotatug deruxtecan
|
|||||
| Synonyms |
raludotatug deruxtecan; DS-6000; DS-6000a; R-DXd; MK-5909
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo (Originator);Merck & Co. (Top20 MNC)
|
|||||
| Drug Status |
Phase 2/3
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Raludotatug
|
Antibody Info | ||||
| Antigen Name |
Cadherin-6 (CDH6)
|
Antigen Info | ||||
| Payload Name |
DXd
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
deruxtecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biliary tract cancer |
1 Trials
|
||||||||||||||
| Cervical cancer |
1 Trials
|
||||||||||||||
| Colorectal cancer |
1 Trials
|
||||||||||||||
| Endometrial cancer |
1 Trials
|
||||||||||||||
| Fallopian tube cancer |
1 Trials
|
1 Trials
|
|||||||||||||
| Gastric cancer |
1 Trials
|
||||||||||||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
||||||||||||||
| Kidney cancer |
1 Trials
|
1 Trials
|
|||||||||||||
| Lung cancer |
1 Trials
|
2 Trials
|
|||||||||||||
| Oesophageal cancer |
1 Trials
|
||||||||||||||
| Ovarian cancer |
1 Trials
|
1 Trials
|
1 Trials
|
1 Trials
|
|||||||||||
| Pancreatic cancer |
1 Trials
|
||||||||||||||
| Peritoneal cancer |
1 Trials
|
1 Trials
|
|||||||||||||
| Unspecific solid tumor |
2 Trials
|
||||||||||||||
| Urothelial cancer |
1 Trials
|